ERBB2 and breast carcinoma: The monoclonal antibody trastuzumab binds to the HER2 receptor and is expressed abundantly on the breast cancer cell line surface [24], and it causes a reduction in the dose-dependent growth of HER2-positive breast cancer cells [25].